ObsEva makes cuts to leadership team, board of directors in another attempt to stay afloat
Women’s health biotech ObsEva is downsizing its US-based executive team and board of directors, the company announced Friday, the latest in a series of austerity measures.
Brian O’Callaghan stepped down as CEO on Feb. 23. The chief commercial officer, chief clinical officer and chief transformation officer also left ObsEva on Thursday. The current CFO, Will Brown, will take on a second role as interim CEO while the company searches for a permanent leader.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.